Abstract
The present study investigates the specific drug targeting of anti cancer drugs, such as carboplatin by incorporation into folate conjugated Solid Lipid Nanoparticles (SLN). Our results showed that SLN 5 has the greater entrapment efficiency of 87.50% and slow in-vitro drug release (65.31% of carboplatin was released in 12 hrs) among all the SLN formulations prepared by high speed homogenization using 23 factorial design. Then SLN 5 was further conjugated with folic acid and its mean particle size (312.208 nm) and in-vitro drug release in 12 hrs (63.43 %) were determined. The comparative in-vitro cytotoxicity for market formulation (Kemocarb), SLN and folate conjugated SLN was determined by MTT assay in Hep 2 cell line and the results showed that folate conjugated SLN has greater cytotoxicity of 70.64 % as it can specifically target the cancer cells through the folate receptors. In-vivo studies were carried out in female Wistar rats and the pharmacokinetic parameters were determined for the market formulation and folate conjugated SLN. The increase in the MRT and AUC values reflects the sustained release effect of folate conjugated SLN formulation and it confirms that it acts as a slow release carrier of carboplatin.
Keywords: Cancer, Carboplatin, Folate receptor, Hep 2 cell line, Solid Lipid Nanoparticles, Targeted drug delivery, anti-cancer agents, tumor site, polymer conjugates, polymeric micelles, solid lipid nanoparticles, liposomes, intracellular, Solid Lipid, High Speed Homogenization.
Drug Delivery Letters
Title:Folate Conjugated Solid Lipid Nanoparticles of Carboplatin for Targeting Cancer Cells
Volume: 2 Issue: 3
Author(s): V. Sankar, Shalini Devi Penmetsa and C. Sabarinath
Affiliation:
Keywords: Cancer, Carboplatin, Folate receptor, Hep 2 cell line, Solid Lipid Nanoparticles, Targeted drug delivery, anti-cancer agents, tumor site, polymer conjugates, polymeric micelles, solid lipid nanoparticles, liposomes, intracellular, Solid Lipid, High Speed Homogenization.
Abstract: The present study investigates the specific drug targeting of anti cancer drugs, such as carboplatin by incorporation into folate conjugated Solid Lipid Nanoparticles (SLN). Our results showed that SLN 5 has the greater entrapment efficiency of 87.50% and slow in-vitro drug release (65.31% of carboplatin was released in 12 hrs) among all the SLN formulations prepared by high speed homogenization using 23 factorial design. Then SLN 5 was further conjugated with folic acid and its mean particle size (312.208 nm) and in-vitro drug release in 12 hrs (63.43 %) were determined. The comparative in-vitro cytotoxicity for market formulation (Kemocarb), SLN and folate conjugated SLN was determined by MTT assay in Hep 2 cell line and the results showed that folate conjugated SLN has greater cytotoxicity of 70.64 % as it can specifically target the cancer cells through the folate receptors. In-vivo studies were carried out in female Wistar rats and the pharmacokinetic parameters were determined for the market formulation and folate conjugated SLN. The increase in the MRT and AUC values reflects the sustained release effect of folate conjugated SLN formulation and it confirms that it acts as a slow release carrier of carboplatin.
Export Options
About this article
Cite this article as:
Sankar V., Devi Penmetsa Shalini and Sabarinath C., Folate Conjugated Solid Lipid Nanoparticles of Carboplatin for Targeting Cancer Cells, Drug Delivery Letters 2012; 2 (3) . https://dx.doi.org/10.2174/2210304x11202030162
DOI https://dx.doi.org/10.2174/2210304x11202030162 |
Print ISSN 2210-3031 |
Publisher Name Bentham Science Publisher |
Online ISSN 2210-304X |
Call for Papers in Thematic Issues
Nanomaterial Assisted Targeted Therapies for Chronic Disorders- Preclinical to Clinical Outcomes
In recent years, the integration of nanomaterials into therapeutic strategies has emerged as a promising avenue in the pursuit of more effective treatments for chronic disorders. This dynamic field, explored in the context of "Nanomaterial Assisted Targeted Therapies for Chronic Disorders - Preclinical to Clinical Outcomes," seeks to bridge the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Current Management of Neonatal Soft-tissue Sarcomas and Benign Tumors with Local Aggressiveness
Current Pediatric Reviews Targeting of Adhesion Molecules as a Therapeutic Strategy in Multiple Myeloma
Current Cancer Drug Targets Monocyte Dependent Regulation of Autoimmune Inflammation
Current Molecular Medicine Antiangiogenic Drugs and Tyrosine Kinases
Anti-Cancer Agents in Medicinal Chemistry CD44 and its Role in Inflammation and Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Lactoferrin Derived Peptides: Mechanisms of Action and their Perspectives as Antimicrobial and Antitumoral Agents
Mini-Reviews in Medicinal Chemistry Assessment In Vitro of a Novel Therapeutic Strategy for Glioma, Combining Herpes Simplex Virus HSV1716-mediated Oncolysis with Gene Transfer and Targeted Radiotherapy
Medicinal Chemistry Inhibitors of Apoptosis Proteins (IAPs) as Potential Molecular Targets for Therapy of Hematological Malignancies
Current Molecular Medicine Cervical Cancer: Are There Potential New Targets? An Update on Preclinical and Clinical Results
Current Drug Targets Radiation-Induced Oral Mucositis in Head and Neck Cancer Patients. Five Years Literature Review
Reviews on Recent Clinical Trials Chemopreventive Properties of Tolfenamic Acid: A Mechanistic Review
Current Medicinal Chemistry Epigallocatechin-3-gallate(EGCG): Mechanisms and the Combined Applications
Combinatorial Chemistry & High Throughput Screening Training Children to Reduce Motion and Increase Success of MRI Scanning
Current Medical Imaging Specific Targeted Therapy: A New Tool for the Destruction of Cancer
Current Drug Therapy Tumor Stroma Manipulation By MSC
Current Drug Targets Ultrasound Contrast Imaging in Cancer –Technical Aspects and Prospects
Current Molecular Imaging (Discontinued) Genetically Engineered Elastin-based Biomaterials for Biomedical Applications
Current Medicinal Chemistry Recent Patents and Patent Applications Relating to mTOR Pathway
Recent Patents on DNA & Gene Sequences Targeting Angiogenesis in Thyroid Cancer
Current Angiogenesis (Discontinued) Role of Carbon Monoxide in Kidney Function: Is a little Carbon Monoxide Good for the Kidney?
Current Pharmaceutical Biotechnology